These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21715107)

  • 1. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
    Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
    Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
    Bisaga A; Sullivan MA; Glass A; Mishlen K; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
    J Subst Abuse Treat; 2014; 46(5):546-52. PubMed ID: 24560438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Problem drinking and low-dose naltrexone-assisted opioid detoxification.
    Mannelli P; Peindl K; Patkar AA; Wu LT; Tharwani HM; Gorelick DA
    J Stud Alcohol Drugs; 2011 May; 72(3):507-13. PubMed ID: 21513688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
    Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
    Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
    Bisaga A; Comer SD; Ward AS; Popik P; Kleber HD; Fischman MW
    Psychopharmacology (Berl); 2001 Aug; 157(1):1-10. PubMed ID: 11512037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
    Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
    Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
    Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
    Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
    Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
    Sinha R; Kimmerling A; Doebrick C; Kosten TR
    Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
    Zakharova E; Malyshkin A; Kashkin V; Neznanova O; Sukhotina I; Danysz W; Bespalov A
    Behav Pharmacol; 2004 Jul; 15(4):273-8. PubMed ID: 15252277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
    Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
    Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
    Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP
    Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.
    Jayaram-Lindström N; Hammarberg A; Beck O; Franck J
    Am J Psychiatry; 2008 Nov; 165(11):1442-8. PubMed ID: 18765480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.
    Aklin WM; Severtson SG; Umbricht A; Fingerhood M; Bigelow GE; Lejuez CW; Silverman K
    J Clin Psychiatry; 2012 Aug; 73(8):e1056-61. PubMed ID: 22967782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone shortened opioid detoxification with buprenorphine.
    Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
    Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia.
    Harris AC; Rothwell PE; Gewirtz JC
    Psychopharmacology (Berl); 2008 Mar; 196(4):649-60. PubMed ID: 18026718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.